Shares of Cyclerion Therapeutics jumped over 160% in pre-market trading after the company announced an all-stock merger agreement with privately held Korsana Biosciences. Korsana is developing next-generation therapies for neurodegenerative diseases, and the announced combination drove a large immediate rerating of Cyclerion's equity.
Shares of Cyclerion Therapeutics jumped over 160% in pre-market trading after the company announced an all-stock merger agreement with privately held Korsana Biosciences. Korsana is developing next-generation therapies for neurodegenerative diseases, and the announced combination drove a large immediate rerating of Cyclerion's equity.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.75
Ticker Sentiment
